These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 9149744

  • 1. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.
    Levine JE, Cohen A, MacQueen M, Martin M, Giardina PJ.
    J Pediatr Hematol Oncol; 1997; 19(2):139-41. PubMed ID: 9149744
    [Abstract] [Full Text] [Related]

  • 2. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine.
    Viola F, Barteselli G, Dell'arti L, Vezzola D, Villani E, Mapelli C, Zanaboni L, Cappellini MD, Ratiglia R.
    Ophthalmology; 2012 Aug; 119(8):1693-700. PubMed ID: 22480740
    [Abstract] [Full Text] [Related]

  • 3. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.
    Styles LA, Vichinsky EP.
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):42-5. PubMed ID: 8556369
    [Abstract] [Full Text] [Related]

  • 4. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T, Ferro G, Frontini V, Percolla S.
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study.
    Piccioni MG, Capone C, Vena F, Del Negro V, Schiavi MC, D'Ambrosio V, Giancotti A, Smacchia MP, Brunelli R.
    Taiwan J Obstet Gynecol; 2020 Jan; 59(1):120-122. PubMed ID: 32039778
    [Abstract] [Full Text] [Related]

  • 8. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N.
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [Abstract] [Full Text] [Related]

  • 9. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Dec; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 10. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population.
    Baath JS, Lam WC, Kirby M, Chun A.
    Retina; 2008 Jun; 28(6):894-9. PubMed ID: 18536609
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 15. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 16. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G.
    Haematologica; 1991 Aug 15; 76(2):131-4. PubMed ID: 1937171
    [Abstract] [Full Text] [Related]

  • 17. Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results.
    Thuret I, Hacini M, Pégourié-Bandelier B, Gardembas-Pain M, Bisot-Locard S, Merlat-Guitard A, Bachir D.
    Hematology; 2009 Dec 15; 14(6):315-22. PubMed ID: 19941737
    [Abstract] [Full Text] [Related]

  • 18. Deferoxamine-induced platyspondyly in hypertransfused thalassemic patients.
    Levin TL, Sheth S, Berdon WE, Ruzal-Shapiro C, Piomelli S.
    Pediatr Radiol; 1995 Nov 15; 25 Suppl 1():S122-4. PubMed ID: 8577502
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun 15; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.